Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLR NASDAQ:ANIX NASDAQ:CUE NASDAQ:ENGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.54+1.3%$1.25$0.77▼$2.35$23.50M0.38210,241 shs100,887 shsANIXAnixa Biosciences$2.90-1.7%$2.83$2.44▼$5.46$98.91M0.64119,941 shs98,575 shsCUECue Biopharma$29.47+0.7%$236.32$4.97▼$41.42$95.25M2.371.56 million shs132,943 shsENGNenGene$1.54+6.9%$6.92$1.40▼$12.25$96.46M-0.022.95 million shs2.49 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+1.32%+4.05%+29.41%+82.18%+48.08%ANIXAnixa Biosciences-1.69%-5.23%+1.75%+3.20%+8.61%CUECue Biopharma+0.72%-13.27%-93.07%-89.09%-95.74%ENGNenGene+6.94%-82.60%-79.27%-84.51%-46.53%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.54+1.3%$1.25$0.77▼$2.35$23.50M0.38210,241 shs100,887 shsANIXAnixa Biosciences$2.90-1.7%$2.83$2.44▼$5.46$98.91M0.64119,941 shs98,575 shsCUECue Biopharma$29.47+0.7%$236.32$4.97▼$41.42$95.25M2.371.56 million shs132,943 shsENGNenGene$1.54+6.9%$6.92$1.40▼$12.25$96.46M-0.022.95 million shs2.49 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics+1.32%+4.05%+29.41%+82.18%+48.08%ANIXAnixa Biosciences-1.69%-5.23%+1.75%+3.20%+8.61%CUECue Biopharma+0.72%-13.27%-93.07%-89.09%-95.74%ENGNenGene+6.94%-82.60%-79.27%-84.51%-46.53%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 2.00Hold$9.75533.12% UpsideANIXAnixa Biosciences 2.25Hold$8.50193.10% UpsideCUECue Biopharma 1.00SellN/AN/AENGNenGene 2.21Hold$13.41770.72% UpsideCurrent Analyst Ratings BreakdownLatest ALLR, CUE, ANIX, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.005/8/2026ENGNenGene CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Outperform ➝ Market Perform5/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$25.00 ➝ $2.005/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$2.005/8/2026ENGNenGene Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/8/2026ENGNenGene Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$2.005/8/2026ENGNenGene Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight5/8/2026ENGNenGene OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/8/2026ENGNenGene HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $6.004/20/2026ALLRAllarity Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity Therapeutics$320K74.40N/AN/A$0.61 per share2.52ANIXAnixa Biosciences$210K463.03N/AN/A$0.42 per share6.90CUECue Biopharma$27.47M3.50N/AN/A$10.08 per share2.92ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$11.23M-$0.80N/AN/AN/AN/A-85.29%-49.92%N/AANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%5/27/2026 (Estimated)CUECue Biopharma-$26.60M-$9.61N/AN/AN/A-96.85%-165.19%-77.77%N/AENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%6/11/2026 (Estimated)Latest ALLR, CUE, ANIX, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/27/2026Q2 2026ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A3/30/2026Q4 2025ALLRAllarity Therapeutics-$0.22-$0.21+$0.01-$0.21N/AN/A3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/A3/9/2026Q1 2026ENGNenGene-$0.55-$0.44+$0.11-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/ACUECue BiopharmaN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.132.13ANIXAnixa BiosciencesN/A12.1812.18CUECue BiopharmaN/A2.742.74ENGNenGene0.0911.7511.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%ANIXAnixa Biosciences29.13%CUECue Biopharma35.04%ENGNenGene64.16%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.08%ANIXAnixa Biosciences26.40%CUECue Biopharma1.82%ENGNenGene10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.46 million15.45 millionNot OptionableANIXAnixa Biosciences533.53 million24.68 millionOptionableCUECue Biopharma603.26 million3.20 millionOptionableENGNenGene3166.99 million60.02 millionN/AALLR, CUE, ANIX, and ENGN HeadlinesRecent News About These CompaniesThe Little Toyota Sports Car Engine That Gave Bigger Rivals A Run For Their MoneyMay 11 at 7:40 PM | msn.comA 1.4L Chevy Spark Engine Doesn’t Sound Too Crazy Until You Put It in a PolarisMay 11 at 7:40 PM | msn.comPratt & Whitney clears key hurdle for XA103 engine for US’ next-gen fighter jetMay 11 at 7:40 PM | msn.comRecord-Setting Hydrogen Engine Rivals Diesel Power With None Of The EmissionsMay 11 at 7:40 PM | slashgear.comSStockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer TherapyMay 10, 2026 | genengnews.comGenGene Therapeutics Inc. (ENGN) Discusses Pivotal Cohort Data from LEGEND Trial of Detalimogene in High-Risk NMIBC TranscriptMay 9, 2026 | seekingalpha.comCitizens downgrades enGene Therapeutics (ENGN)May 9, 2026 | msn.comenGene (NASDAQ:ENGN) Cut to Hold at Wells Fargo & CompanyMay 9, 2026 | marketbeat.comenGene Bladder Cancer Data Shows Promise, but Durability Questions RemainMay 8, 2026 | marketbeat.comFour sub-$1,000 methods for boosting most engines' horsepower, ranked by easinessMay 8, 2026 | msn.comThis groundbreaking hydrogen engine could rival diesel power without the emissionsMay 8, 2026 | msn.comenGene (NASDAQ:ENGN) Rating Lowered to "Market Perform" at Citizens JmpMay 8, 2026 | marketbeat.comenGene (NASDAQ:ENGN) Downgraded by Leerink Partners to "Market Perform"May 8, 2026 | marketbeat.comenGene (NASDAQ:ENGN) Rating Lowered to "Equal Weight" at Morgan StanleyMay 8, 2026 | marketbeat.comenGene (NASDAQ:ENGN) Cut to Market Perform at OppenheimerMay 8, 2026 | marketbeat.comHC Wainwright Lowers enGene (NASDAQ:ENGN) Price Target to $6.00May 8, 2026 | marketbeat.comenGene (NASDAQ:ENGN) Reaches New 52-Week Low - Time to Sell?May 7, 2026 | marketbeat.comHere's How Many Diesel Engines Modern Cruise Ships UseMay 7, 2026 | slashgear.comSHow far can an airplane glide if it loses its engines?May 7, 2026 | msn.comenGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesMay 7, 2026 | globenewswire.comWhy is the Ford 427 V8 engine called the side-oiler?May 7, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026From CrowdStrike to Chewy, These Tanking Stocks Are Announcing BuybacksBy Leo Miller | April 14, 2026ALLR, CUE, ANIX, and ENGN Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.54 +0.02 (+1.32%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$1.55 +0.01 (+0.78%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Anixa Biosciences NASDAQ:ANIX$2.90 -0.05 (-1.69%) As of 05/13/2026 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Cue Biopharma NASDAQ:CUE$29.47 +0.21 (+0.72%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$29.25 -0.22 (-0.75%) As of 04:48 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.enGene NASDAQ:ENGN$1.54 +0.10 (+6.94%) Closing price 05/13/2026 04:00 PM EasternExtended Trading$1.55 +0.01 (+0.65%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nebius Upside Expands as AI Feedback Loop Intensifies Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell Qualcomm Stock Doubles: New Era? Or Another False Start? D-Wave Earnings Looked Weak, But Investors May Be Missing This A Quantum Shift: Why Speculative Money Is Ditching AI Plug Power Flips The Switch On Profitability Reading the Stripes: Is The Industrial Recession Over? How Bad Could Tesla’s Cybertruck Recall Be for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
